19 completed, 5 terminated, 1 withdrawn. 25 Phase 1, 9 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 25 | Completed 19, Terminated 5, Withdrawn 1 |
| Phase 2 | 9 | Completed 5, Terminated 3, Withdrawn 1 |
Follow Introns: new trials by email Literature Review of Introns trials Research Report on Introns
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Rintatolimod and IFN Alpha-2b for the Treatment of COVID-19 in Cancer Patients Recombinant Interferon Alfa-2b, Rintatolimod - Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm | Phase 1 / Phase 2 | Terminated | Roswell Park Cancer Institute | 4 | 2020-11-17 | 2026-01-13 |
| Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer Celecoxib, Cyclophosphamide, Doxorubicin - Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8 | Phase 1 | Completed | Roswell Park Cancer Institute | 9 | 2019-12-06 | 2023-09-11 |
| SV-BR-1-GM in Metastatic or Locally Recurrent Breast Cancer SV-BR-1-GM, Cyclophosphamide, Interferon-alpha-2b - Breastcancer, Breast Neoplasm | Phase 1 / Phase 2 | Completed | BriaCell Therapeutics Corporation | 24 | 2017-05-05 | 2021-01-29 |
| Study of Recombinant Human Serum Albumin/Interferon alpha2b Fusion Protein in Chinese Healthy Volunteers Human Serum Albumin/interferon alpha2b, Peginterferon 180 μg single dose S.C. - Healthy | Phase 1 | Completed | Tianjin SinoBiotech Ltd. | 34 | 2016-04-07 | 2017-05-08 |
| Neoadjuvant Combination Biotherapy With Pembrolizumab and High Dose IFN-alfa2b Pembrolizumab and high dose interferon alfa-2b (HDI) - Melanoma | Phase 1 | Completed | Yana Najjar | 31 | 2015-03-06 | 2021-02-24 |
| αDC1 Vaccine + Chemokine Modulatory Regimen (CKM) as Adjuvant Treatment of Peritoneal Surface Malignancies DC vaccine, Celecoxib, Interferon Alfa-2b - Malignant Neoplasm of Pancreas Metastatic to Peritoneal Surface, Malignant Peritoneal Mesothelioma | Phase 1 / Phase 2 | Completed | David Bartlett | 64 | 2014-07-01 | 2020-07-20 |
| Systemic Therapy With Interferon, Interleukin-2 and BRAF Inhibitor Vemurafenib, IL-2, Interferon Alpha-2b - Melanoma | Phase 1 | Completed | M.D. Anderson Cancer Center | 6 | 2013-07-18 | 2019-05-21 |
| IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma Ipilimumab, Temozolomide, Cisplatin - Melanoma | Phase 1 | Terminated | M.D. Anderson Cancer Center | 19 | 2013-02-01 | 2017-05-31 |
| Chemokine-Modulatory Regimen for Recurrent Resectable Colorectal Cancer Chemokin Modulatory Regimen (5 MU/m2), Chemokin Modulatory Regimen (10 MU/m2), Chemokin Modulatory Regimen (20 MU/m2) - Colorectal Cancer, Colorectal Carcinoma | Phase 1 / Phase 2 | Terminated | Roswell Park Cancer Institute | 15 | 2012-10-01 | 2023-10-27 |
| Multiple Antigen-Engineered DC Vaccine for Melanoma DC Vaccine + IFN, AdVTMM2/DC Vaccination - Melanoma | Phase 1 | Completed | Lisa H. Butterfield, Ph.D. | 35 | 2012-06-01 | 2017-08-31 |
| IPI-Biotherapy for Patients Previously Treated With Cytotoxic Drugs With Metastatic Melanoma Ipilimumab, Interferon, Interleukin-2 (Aldesleukin) - Melanoma | Phase 1 / Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2011-10-01 | 2012-01-26 | |
| Biochemotherapy and Bevacizumab Followed by Consolidation Therapy With Ipilimumab for Metastatic Melanoma Biochemo + bevacizumab then ipilimumab - Metastatic Melanoma | Phase 1 / Phase 2 | Completed | California Pacific Medical Center Research Institute | 24 | 2010-12-01 | 2013-08-29 |
| Differences in Evoked Intracellular Interferon Signaling Pathways Using Single Cell Phosphoprotein Profiling Interferon Alfa-2b - Hepatitis C | Phase 1 | Completed | University of North Carolina, Chapel Hill | 22 | 2010-05-01 | 2016-11-15 |
| A Phase I/II Clinical Trial With Interferon Alfa 5 in Treatment-Experienced Patients With Genotype-1 Chronic Hepatitis C Interferon α-5, Interferon-α5 plus Interferon-α 2b, Interferon α-2b (INTRON® A) - Chronic Hepatitis C Virus Infection, Genotype 1 | Phase 1 / Phase 2 | Completed | Digna Biotech S.L. | 70 | 2010-05-01 | 2013-02-05 |
| Cisplatin, Temozolomide, Abraxane, With Interleukin-2 and Interferon for Metastatic Melanoma Temozolomide, Abraxane, Cisplatin - Melanoma | Phase 1 | Completed | M.D. Anderson Cancer Center | 10 | 2009-09-01 | 2013-01-03 |
| Study of Pegylated Alfa Interferon, Sunitinib and Tarceva in Patients With Metastatic RCC Pegylated Alfa Interferon, sunitinib, erlotinib - Carcinoma, Renal Cell | Phase 1 / Phase 2 | Terminated | The Methodist Hospital Research Institute | 10 | 2007-05-01 | 2016-03-17 |
| Sodium Stibogluconate and IFNa-2b Followed By CDDP, VLB and DTIC Treating Pts.With Advanced Melanoma or Other Cancers recombinant interferon alfa-2b, cisplatin, sodium stibogluconate - Stage IV Melanoma | Phase 1 | Completed | Case Comprehensive Cancer Center | 22 | 2007-05-01 | 2020-07-24 |
| Sodium Stibogluconate With Interferon Alpha-2b for Patients With Advanced Malignancies Sodium Stibogluconate, Interferon Alpha-2b - Advanced Cancer, Solid Tumors | Phase 1 | Completed | M.D. Anderson Cancer Center | 33 | 2006-09-13 | 2018-11-15 |
| Azacitidine and Interferon Alfa in Treating Patients With Metastatic Melanoma recombinant interferon alfa-2b, azacitidine - Melanoma (Skin) | Phase 1 | Completed | University of California, San Diego | 12 | 2006-02-01 | 2021-03-03 |
| Sodium Stibogluconate and Interferon in Treating Patients With Advanced Solid Tumors, Lymphoma, or Myeloma recombinant interferon alfa-2b, sodium stibogluconate, SSG & interferon - Cancer | Phase 1 | Terminated | The Cleveland Clinic | 18 | 2005-10-01 | 2018-01-26 |
Showing 20 of 25. Sign in to see all of them.
Melanoma (12) · Recurrence (5) · Carcinoma, Renal Cell (3) · Neoplasm Metastasis (3) · Breast Neoplasms (2) · Neoplasms (2) · Astrocytoma (1) · Brain Neoplasms (1) · Breast Carcinoma In Situ (1) · Carcinoma, Hepatocellular (1) · Colorectal Neoplasms (1) · Ependymoma (1) · Glioblastoma (1) · Glioma (1) · Glioma, Subependymal (1)
M.D. Anderson Cancer Center (6) · Roswell Park Cancer Institute (3) · National Cancer Institute (NCI) (2) · BriaCell Therapeutics Corporation (1) · California Pacific Medical Center Research Institute (1) · Case Comprehensive Cancer Center (1) · David Bartlett (1) · Digna Biotech S.L. (1) · Endocyte (1) · Lisa H. Butterfield, Ph.D. (1) · The Cleveland Clinic (1) · The Methodist Hospital Research Institute (1) · The University of Hong Kong (1) · Tianjin SinoBiotech Ltd. (1) · University of California, San Diego (1)
United States (21) · China (1) · Spain (1)
Ernest C. Borden, MD (2) · Rodabe N. Amaria, MD (2) · Agop Y. Bedikian, MD,BS (1) · Amer H Zureikat, MD (1) · Ashish M. Kamat, MD (1) · Aung Naing, MD (1) · Chung Mau Lo, MS (1) · David L Bartlett, MD (1) · David R Minor, MD (1) · George E Peoples, MD, FACS (1) · Gregory A. Daniels, MD, PhD (1) · Igor Puzanov (1) · John M Kirkwood, MD (1) · Mario Sznol (1)
2009 (1), P01CA132714 (1), P30CA016056 (1), P30CA016058 (1), P30CA016672 (1), P30CA043703 (1), P50CA091846 (1), P50CA121973 (1), U01CA076576 (1), UL1TR001412 (1)